Japanese cedar/cypress pollinosis updated: new allergen, cross-reactivity, and treatment
-
- Osada Toshihiro
- Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd.
-
- Okano Mitsuhiro
- Department of Otorhinolaryngology, International University of Health and Welfare School of Medicine
書誌事項
- タイトル別名
-
- Japanese cedar and cypress pollinosis updated: New allergens, cross-reactivity, and treatment
この論文をさがす
説明
<p>Pollen from many tree species in the Cupressaceae family is a well-known cause of seasonal allergic diseases worldwide. Japanese cedar pollinosis and Japanese cypress pollinosis, which are caused by pollen from Japanese cedar (Cryptomeria japonica) and Japanese cypress (Chamaecyparis obtusa), respectively, are the most prevalent seasonal allergic diseases in Japan. Recently, the novel major Japanese cypress allergen Cha o 3 and the homologous Japanese cedar allergen Cry j cellulase were identified, and it was shown, for the first time, that cellulase in plants is allergenic. Although the allergenic components of pollen from both species exhibit high amino acid sequence identity, their pollinosis responded differently to allergen-specific immunotherapy (ASIT) using a standardized extract of Japanese cedar pollen. Pharmacotherapy and ASIT for Japanese cedar and cypress pollinosis have advanced considerably in recent years. In particular, Japanese cedar ASIT has entered a new phase, primarily in response to the generation of updated efficacy data and the development of new formulations. In this review, we focus on both Japanese cypress and cedar pollinosis, and discuss the latest findings, newly identified causative allergens, and new treatments. To manage pollinosis symptoms during spring effectively, ASIT for both Japanese cedar and Japanese cypress pollen is considered necessary.</p>
収録刊行物
-
- Allergology International
-
Allergology International 70 (3), 281-290, 2021
一般社団法人日本アレルギー学会